丙丁酚改善缺血性心肌病心力衰竭患者心功能及机制研究

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (11): 1282-1287.

丙丁酚改善缺血性心肌病心力衰竭患者心功能及机制研究

任宁, 唐惠芳

南华大学附属第一医院心血管内科,衡阳 421001,湖南

收稿日期:2011-05-31 修回日期:2011-09-25 出版日期:2011-11-26 发布日期:2011-11-29
通讯作者: 唐惠芳,博士,副教授,硕士研究生导师,主要从事心衰和心血管疾病电生理研究。Tel: 0734-8279335 E-mail: tanghuifang999@163.com
作者简介:任宁,硕士,主要从事心力衰竭方面研究。Tel: 15096075130 E-mail: 26267274@qq.com
基金资助:
国家自然科学基金——心房颤动相关miRNA的鉴定及其功能研究(30900625)资助;受诺美抗氧化临床研究基金

Effects and mechanism of probucol on cardic function in patients with ischemic cardiomyopathy heart failure

REN Ning, TANG Hui-fang

The First Affiliated Hospital of Nanhua University, Hengyang 421001, Hunan, China

Received:2011-05-31 Revised:2011-09-25 Online:2011-11-26 Published:2011-11-29

摘要/Abstract

摘要： 目的: 探讨丙丁酚改善缺血性心肌病(ischemic cardiomyopathy, ICM)心力衰竭患者心功能及其机制。方法: 选择36例ICM心力衰竭患者,随机分为丙丁酚组和常规治疗组,各18例。两组患者均接受调脂、抗血小板和抗心肌缺血的基础治疗以及常规抗心衰治疗,丙丁酚组在常规治疗基础上加用丙丁酚片。治疗初及治疗6个月后观察两组患者下列指标的变化情况:NYHA心功能分级;血脂指标:TC、TG、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C);氧化应激指标:氧化低密度脂蛋白(ox-LDL)、丙二醛(MDA)、超氧化物岐化酶(SOD);炎症标志物:高敏C反应蛋白(hs-CRP)、红细胞沉降率(ESR);超声心动图指标:左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)和左室射血分数(LVEF)。结果: 治疗6个月后,与常规治疗组比较,丙丁酚组患者MDA明显降低(P<0.05),ox-LDL明显降低(P<0.01),SOD明显增高(P<0.01),NYHA心功能分级有效率明显增加(P<0.05),LVEF有增加的趋向,但比较差异无统计学意义(P>0.05)。治疗6个月后,与常规治疗组比较,丙丁酚对于TG、HDL-C、LDL-C、hs-CRP、ESR、LVEDD和LVESD的改变无统计学意义。结论: 丙丁酚改善ICM心力衰竭患者心衰的作用与其抗氧化作用有关,与其调脂作用无关。

关键词: 丙丁酚, 缺血性心肌病, 心力衰竭, 心功能

Abstract: AIM: To explore the effects and mechanism of probucol on cardic function in patients with ischemic cardiomyopathy (ICM) heart failure.METHODS: 36 patients with ICM heart failure were randomly divided into probucol group and conventional therapy group (n=18 in each group). Both groups were given therapy of regulating blood lipid, antiplatelet, anti-ischemia and conventional anti-heart failure therapy. Probucol group was additionally given with probucol. The following changes of both groups were determined before and after treatment for six months respectively: cardiac function classification; blood lipids: total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C); oxidative stress indices: oxidized low-density lipoproteins (ox-LDL), malondialdehyde (MDA), superoxide dismutase (SOD); markers of inflammation: high sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR); echocardiography parameters: left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular ejection fraction (LVEF).RESULTS: After six months of treatment, compared with the conventional therapy group, probucol decreased the levels of MDA (P<0.05), decreased the level of ox-LDL (P<0.01), increased the level of SOD (P<0.01), and increased the improving rate of cardiac function in observation group (P<0.05). Compared with the conventional therapy group, there was a growing trend towards LVEF in the observation group, but there was no significant difference between two groups. After six months of treatment, compared with the conventional therapy group, the changes of TG, HDL-C, LDL-C, hs-CRP, ESR, LVEDD and LVESD by Probucol had no statistical significance.CONCLUSION: The effect of probucol on ICM heart failure may be related with anti-oxidation and may not be related with lipid-lowering efficacies.

Key words: Probucol, Ischemic cardiomyopathy, Heart failure, Cardiac function

中图分类号:

R969.4

任宁, 唐惠芳. 丙丁酚改善缺血性心肌病心力衰竭患者心功能及机制研究[J]. 中国临床药理学与治疗学, 2011, 16(11): 1282-1287.

REN Ning, TANG Hui-fang. Effects and mechanism of probucol on cardic function in patients with ischemic cardiomyopathy heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1282-1287.

参考文献

[1] 戴闺柱, 黄峻. 2007慢性心力衰竭诊断治疗指南[J]. 中华心血管病杂志, 2007,36(12): 1076-1095.
[2] 游建林. 福辛普利联合美托洛尔治疗慢性心力衰竭的疗效[J]. 医药导报, 2008, 27(4): 421-422.
[3] EI-Demerdash E, Award AS, Taha RM, et al. Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat[J]. Pharmacol Res, 2005, 51(4): 311-318.
[4] 张慧平, 孙福成. B型利钠肽与心力衰竭[J]. 中华老年医学杂志, 2005, 24(10): 790-793.
[5] 李婷婷. 普罗布考的研究进展及应用前景[J]. 心血管病学进展, 2009, 30(4): 649-653.
[6] Torre-Amione G. Immune activation in chronic heart failure[J]. Am J Cardiol, 2005, 95(11A): 3C-8C.
[7] Kawamoto R, Yamashita A, Nishihira K, et al. Different inflammatory response and oxidative stress in neointimal hyperplasia after balloon angioplasty and stent implantation in cholesterol-fed rabbits[J]. Pathol Res Pract, 2006, 202(6): 447-456.
[8] Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reaetive protein for te targeting of statin therapy in the primary prevention of acute coronary events[N]. Engl J Med, 2001, 344(26): 1959-1965.
[9] Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort [J]. Diabetes, 2004, 53(4): 1068-1073.
[10] Umeji K, Umemoto S, Itoh S, et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR{gamma}, and aortic stiffness in hypercholesterolemia[J]. Am J Physiol Heart Circ Physiol, 2006, 291(5): H2522-2532.
[11] Yi GH, Zhong CM, Yan PY, et al. Effects of probucol on paraoxonase 1 expression and oxidative stress in hyperlipidemic mice [J]. Cell Biol Intern, 2008, 2(1): 67-71 .
[12] 叶延平, 莫中成, 龙治峰, 等. 丙丁酚对动脉粥样硬化小鼠抗氧化作用的比较[J]. 中国动脉硬化杂志, 2008, 16(7): 513-518.

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	张华斌, 罗中旭, 钟民, 洪宗元, 王德国. 脊髓麻醉对大鼠急性心肌缺血再灌注室性心律失常的影响研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 249-256.
[3]	彭勇, 范剑峰, 熊旭华, 肖冬平, 高招波, 郑春华. 右旋糖酐铁片对合并铁缺乏的射血分数减低的心力衰竭患者的影响[J]. 中国临床药理学与治疗学, 2023, 28(2): 178-183.
[4]	陈玉林, 蒋虎刚, 王新强, 刘凯, 李应东, 安涛, 赵信科. 基于网络药理学和分子对接探讨芪参益心颗粒治疗射血分数保留型心力衰竭的作用机制[J]. 中国临床药理学与治疗学, 2023, 28(10): 1081-1092.
[5]	杨胜, 王德国. 沙库巴曲缬沙坦联合达格列净治疗射血分数减低型心力衰竭疗效及对血清cTnⅠ、BNP水平的影响[J]. 中国临床药理学与治疗学, 2022, 27(9): 1010-1015.
[6]	彭娟, 范琳琳, 李然宜, 李晓宇, 吕迁洲, 邹云增. 心力衰竭药物治疗的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 373-381.
[7]	刘平, 邱博, 吴惠珍. 维利西呱治疗心力衰竭的药理作用与临床评价[J]. 中国临床药理学与治疗学, 2022, 27(2): 212-218.
[8]	徐永华, 施向红. 托拉塞米联合左卡尼汀治疗慢性心力衰竭的疗效分析[J]. 中国临床药理学与治疗学, 2021, 26(6): 647-652.
[9]	陈力方, 王博, 王维蓉. 组蛋白去乙酰化酶3在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 88-97.
[10]	胡晓燕, 徐秋萍. 左西孟旦在心脏外科术后重症患者的应用研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1027-1032.
[11]	范剑峰，方译，郑春华. 沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(7): 810-814.
[12]	沈蕾，王柯柯，杨景柯，赵俊涛，孟祥光，袁义强. 心力衰竭治疗药物的表观遗传药理学进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 343-349.
[13]	魏子寒，李栋博，元峥，陆颍，杨国杰. 沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 57-62.
[14]	黄霆，汪和贵. β受体-PKA-AKAP信号通路调控心力衰竭的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(5): 592-596.
[15]	王世彪，王程毅，翁斌，郭晓峰，林海. 无创心输出量监测联合米力农在小儿重症肺炎并心力衰竭中的疗效对比观察及对脑钠肽水平的影响研究[J]. 中国临床药理学与治疗学, 2018, 23(12): 1402-1407.